1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

EU Accelerated Assessment – Hard To Get, Hard To Keep

 
• By Maureen Kenny

It’s hard enough in the first place for companies to persuade the European Medicines Agency that their planned marketing authorization application should be fast-tracked. Many are also finding that after accelerated assessment is granted, it is taken away during the actual review.

Hot air balloons
Fast-track review can give companies an important competitive advantage

Many of the marketing authorization applications (MAAs) that until recently were being evaluated under the European Medicines Agency’s accelerated assessment mechanism have reverted to standard review timelines. The MAAs relate to products such as AveXis’s gene therapy, Zolgensma, and several other products that, like Zolgensma, have already been approved in the US.

Seven MAAs that were originally granted accelerated assessment and were initially being processed under this mechanism are no longer undergoing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

MHRA Backs Bacteriophage Innovation To Fight Antimicrobial Resistance

 
• By Eliza Slawther

The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.

US FDA Cell-Gene Therapy Head Says Agency Has Revived Stalled Programs

 
• By Sarah Karlin-Smith

CBER's Nicole Verdun wants rare disease sponsors with stalled treatments to circle back because the FDA's evolved thinking on clinical trial designs may offer another opportunity for cast away products.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.